Mr Jonathan Walland
Memorial Sloan Kettering Cancer Center — the world’s oldest and largest private cancer center — has devoted more than 130 years to exceptional patient care, innovative research, and outstanding educational programs. Today, we are one of 45 National Cancer Institute–designated Comprehensive Cancer Centers, with state-of-the-art science flourishing side by side with clinical studies and treatment.
The close collaboration between our physicians and scientists is one of our unique strengths, enabling us to provide patients with the best care available as we work to discover more-effective strategies to prevent, control, and ultimately cure cancer in the future. Our education programs train future physicians and scientists, and the knowledge and experience they gain at Memorial Sloan Kettering has an impact on cancer treatment and biomedical research around the world.
Learn more about Memorial Sloan Kettering.
Memorial Sloan-Kettering Cancer CenterAssociate General Counsel
Mr Brian Walsh
Our name, Aptuit, is derived from the words aptitude and intuition, two natural attributes that define our unique approach to providing drug discovery, development and manufacturing support. The name communicates our aptitude for scientific knowledge as well as our intuitive understanding of the needs of the pharmaceutical and biotechnological community. We summon these attributes to clarify current challenges and anticipate those that are to come, always with the determination to find solutions.
Since Aptuit was founded in 2004, we have forged a robust expansion of our resources. We are living up to the promise of our name by the ongoing assembly of experienced and talented scientists, and we are supporting them every step of the way with the most advanced resources at state-of-the art facilities.
Our corporate tagline - Uncommon Expertise. Exceptional Results - reflects our success in harnessing unique and outstanding strengths in drug discovery and drug development to deliver the results that our clients demand.The services we provide to help us achieve this vision are:
AptuitDirector, Buisness Development
Dr Bin Wang
Widener University is a nationally-recognized, private university where academics, leadership, and service matter.
Founded in 1821, Widener is among the nation’s top universities for civic engagement.
We offer liberal arts and sciences and professional programs leading to associate’s, baccalaureate, master’s, and doctoral degrees.
We have a long history of turning out leaders with a formula that works. At Widener, we believe that academic excellence, career preparation, and civic engagement lead to success.
Our close-knit community includes top-notch teachers, nationally renowned researchers, and students from 22 states and 26 countries who are passionate about learning, leadership, and making a difference.
When they are not engaged in experiential learning assignments, our students and faculty members lend a hand through community service projects in our hometown of Chester and in communities around the world.
Widener UniversityAssistant Professor
Mr Robert Ward
Radius is a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases.
Radius is committed to the research and development of new therapeutics for the large and underserved osteoporosis market. The Company's lead investigational drug product candidate, abaloparatide (BA058), is in development, in both injection (Abaloparatide-SC) and transdermal (Abaloparatide-TD) methods of administration, for the potential prevention of fractures in post-menopausal women at risk of fracture from osteoporosis.
Radius' clinical portfolio also includes a new investigational oral agent, RAD1901, a selective estrogen receptor down-regulator/degrader, or SERD, in development at higher doses for the potential treatment of breast cancer brain metastases, and at lower doses as a selective estrogen-receptor modulator, or SERM, for the potential treatment of vasomotor symptoms such as hot flashes.
Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care teaching facility acclaimed internationally for excellence in clinical care.
U.S. News & World Report ranks The Mount Sinai Hospital among the top hospitals nationwide. Mount Sinai also ranks in several specialties and is top 10 in three of those: Geriatrics (#3), Cardiology and Heart Surgery (#7), and Gastroenterology (#8).
Additionally, Kravis Children’s Hospital at Mount Sinai received U.S. News and World Report 2015-2016 rankings in seven pediatric specialties:
- Diabetes and Endocrinology
- Gastroenterology and GI Surgery
- Neurology and Neurosurgery
Icahn School of Medicine at Mount Sinai is internationally recognized as a leader in groundbreaking clinical and basic science research and is known for its innovative approach to medical education.
With a faculty of more than 3,400 in 38 clinical and basic science departments and centers, Mount Sinai ranks among the top 20 medical schools in receipt of National Institutes of Health grants. In its 2012 "America’s Best Graduate Schools" issue, U.S. News & World Report ranks the Icahn School of Medicine 18th out of 126 medical schools nationwide.
Mount SinaiResearch Analyst
Dr Myron Wecker
When it opens in the fall of 2014, the Advanced Science Research Center will bring CUNY to a landmark moment in its decade-long, multi-billion-dollar commitment to becoming a national leader in visionary scientific research of vital, real-world consequence.
A decade in the planning, the first phase of the ASRC is rapidly taking shape on the south end of the City College campus in Upper Manhattan: a striking glass-encased structure that will be at the center of CUNY’s expanding universe of science and embody a bold vision of 21st Century discovery.
The construction of a $350 million building with 200,000 square feet of world-class facilities would be big news for any institution, public or private. But sophistication and scale are only part of the ASRC story. At the center’s core will be an innovative approach to the scientific method itself, one that seeks to break down some of the walls between disparate but increasingly inter-related disciplines of applied science.
The ASRC will focus CUNY initiatives in five of the most energized areas of global research: Nanoscience. Photonics. Structural Biology. Neuroscience. Environmental Sciences.
City University of NY | Center for Advanced TechnologyDeputy Director
Professor Stanley H. Weiss, MD, FACP, FACE
International Epidemiologist with wide ranging expertise in chronic and infectious diseases & interdisciplinary collaborations.
Private email: stanweiss @ verizon.net
Stanley H. Weiss, MD has been on the RBHS (and legacy UMDNJ) faculties since 1987, and currently is Professor (with tenure) of Medicine at the New Jersey Medical School, and Professor of Epidemiology at the Rutgers School of Public Health.
He graduated from Yale (1974, BA, summa cum laude and Phi Beta Kappa) and Harvard Medical School (1978, MD). He did a residency in Internal Medicine at Montefiore in the Bronx, and fellowships at the National Cancer Institute in Medical Oncology and in Epidemiology. Dr. Weiss is Board Certified in Internal Medicine and in Medical Oncology, and a fellow of the American College of Epidemiology (“FACE”) and the American College of Physicians (“FACP”).
On November 2nd, 2015, he will be honored by the American Public Health Association with its Wade Hampton Frost Lecture, its top epidemiology research award.
His past professional awards include the NJ Public Health Association’s (NJPHA) highest award – the Dennis J. Sullivan Award (2012), the NJPHA Dr. Ezra Mundy Hunt Award (2007), the first recipient of the American Lung Association of NJ’s “CAREforAIRnj Award for Community Outreach/Action/Advocacy, the “Cancer Liaison Physician Outstanding Performance Award” from the Commission on Cancer of the American College of Surgeons (2010), the Prostate Net’s “In the Know” National Award (2007), the UMDNJ School of Public Health “Faculty Community Service Award”(2007), and the first of the American Society of Clinical Oncology “Travel Awards” for outstanding work (1985). At NJMS, he was elected to membership in Sigma Xi chapter (1992) and as a Faculty member to the Alpha Omega Alpha [ΑΩΑ] Honor Medical Society, Beta Chapter (inducted 2003). For the latter, he has served as an officer as the Assistant Secretary/Treasurer since 2006, and helped to develop its Research Award.
Dr. Weiss’ research focuses on epidemiology, public health, study design and methodology, evaluation, policy issues and interdisciplinary studies and projects. These have primarily been related to cancer, asthma, retroviruses including HIV/AIDS and HTLV, infectious diseases, methodological and policy issues, and bioethics. In addition, he is the PI of several community-outreach initiatives (including the implementation and evaluation of structured tool sets for individuals to improve their health) and PI/co-PI of a series of studies concerning asthma with key new understanding of asthma epidemiology as well as policy implications. He is the PI of a set of prospective cohort studies numbering ~10,000 injection drug users begun in the 1980’s, over 30 years ago, which is linked to personal identifying information and a biospecimen collection of ~ 100,000 vials.
Dr. Weiss has authored over 350 published, peer-reviewed medical articles, chapters and abstracts. Among his research accomplishments (as lead or senior author, except as noted):
- First assessment of the prototype HIV screening test.
- Part of the team describing the 2nd case worldwide of HTLV-II infection.
- First demonstration of high infection rates with HTLV-II in drug users.
- First report that among persons seropositive for HIV antibody, adverse outcomes had significant latency, and these steadily mounted over time to high rates of severe disease and death.
- First demonstrated US case (2nd worldwide) of occupational acquisition of HIV in healthcare workers, associated this with HIV needlestick) exposure, and leading to vast changes in the workplace.
- First case of occupational acquisition of HV in research workers.
- First US case of HIV-2 – detected at University Hospital, Newark.
- First demonstration of female to male sexual transmission of HIV.
- Part of the team documenting the 2nd case of female to female HIV transmission.
- Wrote substantial parts of the first NJ State Cancer Plan, and then led much of its statewide implementation.
- First demonstration that the latency from initial asbestos exposure until development of mesothelioma is far longer than has been generally understood.
- First to demonstrate that the US epicenter for HIV infection in injection drug users centered about NYC, and the first to enroll women in an HIV-era cohort study.
- First to assess geographic distribution of asthma in children across an entire state.
- First to discover confirmed very high rates of HCV in IDU’s, presaging the epidemic consequences of HCV (liver failure and hepatocellular carcinoma).
- A member of the team demonstrating immunologic abnormalities associated with HTLV-II, such as spontaneous lymphocyte proliferation and lymphocyte subset changes.
Dr. Weiss is the immediate past Chair of the International Joint Policy Committee of the Societies of Epidemiology (see: www.ijpc-se.org). He has continuously served on the Executive Board of the NJPHA since 1993, through the terms of over a dozen NJPHA presidents, and the founding Chair of its Epidemiology Section. He is a past chair of the Epidemiology Section and past vice-chair of the Science Board of the American Public Health Association. He is a longstanding member of the Coordinating Committee of the Pediatric/Adult Asthma Coalition of NJ and co-chair of its Evaluation Workgroup, and the Community Liaison Physician of the NJMS/University Hospital Oncology Program to the CoC and the vice-chair of its Oncology Committee.
As the founder and director of the Essex County Cancer Coalition and of its expanded successor, the Essex-Passaic Chronic Disease Coalition (a.k.a. the Essex-Passaic Wellness Coalition; http://web.njms.rutgers.edu/EPWC), he helps implement community-based education, outreach, screening and prevention of cancer and is a public policy advocate.
His RBHS teaching has focused on evidence-based medicine approaches and critical analysis of medical literature, and the epidemiology and prevention of both chronic and infectious diseases. He served in 2012-13 as the co-course director of the 2nd year NJMS “Disease Processes, Prevention & Therapeutics” course. He also teaches in the RBHS School of Public Health.
Other professional affiliations include the NJ Allergy, Asthma & Immunology Society, the NY Allergy and Asthma Society, the American Society of Clinical Oncology, Alpha Omega Alpha (the medical honor society; he is the assistant secretary-treasurer of the Beta Chapter of NJ), the Society for Epidemiologic Research, the International Epidemiological Association, and one of the Founding Members of the Infectious Disease Society of NJ. He is a past Fellow of the Infectious Diseases Society of America. He’s been in leadership roles for each of the four North American Congresses of Epidemiology.
Rutgers Biomedical and Health Sciences (RBHS) - New Jersey Medical SchoolProfessor of Medicine, Rutgers Biomedical and Health Sciences (RBHS) - NJ Medical School - Prof. of Epidemiology, RBHS School of Public Health
Your innovative solution
Our technology helps automate/standardize image interpretation ; it also enables quantification of standard imaging criteria and advanced imaging biomarkers, to provide early proof of treatment response. Our Lesion Management Solutions (LMS) platform is a proprietary suite of software modules for automated/semi-automated detection, quantitative measurement and follow-up of tumors.
MEDIAN's technology solves frequently observed issues in image interpretation such as intra- and inter-reader variability of measurement or lack of standardization of reading/interpretation processes. Both variability and insufficient level of standardization lead to a decrease of imaging data reliability, which can, for instance impact the statistical power of data in clinical trials.
Oncology drug development -clinical trials (phases I to phases III) / Novel biomarkers development in oncology and other therapeutic areas / Imaging based cancer screening programs
Quantitative and standardized data analysis supported by cutting edge, FDA approved, technology / Expertise in advanced imaging biomarkers for more accurate evaluation of drug efficacy / Real time, streamlined image workflow for clinical trials
MEDIAN TechnologiesVP Business development
Ms Danielle Winningham
The Madison County Economic Development Authority, or MCEDA as we are known locally, offers a broad array of economic development, business development, and corporate site location assistance services to new and expanding businesses and industry.
MCEDA owns the newly created Mississippi Bio-Medical Business Collaboratory. A 60,000 square foot office and educational services facility for bio-medical and medical related companies. We are seeking new tenants for the facility. Current tenants include: TeleHealthOne (telemedicine provider), Xerox, Mississippi Association of Nurse Practitioners, and the Global Training Institute (a brand new state-of-the art Surgical and Medical Simulation Center).